Erasca Q2 2023 net loss $31.8M; cash $365.3M, funding into H2 2025

Erasca, Inc.

2023-Q2 EPS reported -$0.43

Net loss of $31.8M ($0.21/ share) vs $35.6M ($0.30) in Q2 2022; R&D spend $26.2M.
Cash, equivalents, and marketable securities $365.3M as of Jun 30, 2023, down from $435.6M at Dec 31, 2022.
ERAS-007 Phase 1b in BRAFm CRC showed 50% (3/6) response rate; expansion data expected H2 2023–H1 2024.
First patient dosing in SEACRAFT-1 (naporafenib + trametinib) for RAS Q61X tumors expected H2 2023.
FDA granted Fast Track and Orphan Drug Designations for ERAS-801 in recurrent glioblastoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023, EPS $(0.21).

Period: quarter ended June 30, 2023
Net income: Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023
EPS: $(0.21)
Result: reported results

Exact text from the filing

Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041299

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.